Print
Email
Print Edition StoriesThursday, July 9, 2009
Cell Signaling Technology opens European unit
By Mass High Tech staff
MHT's Galen Moore: Hiring trends and opportunities
Breaking down the MIT $100K
MHT's Marc Songini: Researchers focus on macular degeneration
Biomedical research products supplier Cell Signaling Technology Inc. has bought the assets of the company’s Dutch distributor BIOKÉ BV. The acquisition opens up CST market coverage to Europe.
As part of the deal, BIOKÉ will be renamed Cell Signaling Technology Europe, become a wholly owned subsidiary of CST Inc. and start taking European orders at the start of 2010. To date, the company has been using exclusive distributors for European sales.
Danvers-based CST began its global expansion in 2008 when it established a wholly owned subsidiary in Tokyo, which now supplies products to its Japanese customer base.
The expansion to Japan and Europe mark CST’s strategic moves to establish units in “key global markets.”
In March 2007, the company formed an alliance with drug giant Merck & Co. Inc., providing its proteomics technology for biomarker discovery and related expertise to aid Merck’s efforts to develop cancer-fighting drugs.
Established in 1999, privately held Cell Signaling Technology reports about 300 employees.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
